Under the agreement, Novo, which recently changed its name from Novo Nordisk, receives a global license to use Nanexa's pharmaceutical platform Pharmashell in up to five development programs.
"We are very excited and proud of this licensing agreement with Novo and look forward to working with them to successfully develop less frequent dosing products in obesity and type 2 diabetes," says David Westberg, CEO of Nanexa in the press release.
